Shares of Mylan N.V. MYL have gained 7.6% in the last three months, as against the industry’s decline of 3.7%. View photos Mylan’s fourth-quarter results were mixed with the bottom line exceeding expectations but the top line lagging …
Yahoo!2mon
Mylan's EpiPen price hikes made it the face of corporate greed last summer. Now, the drug maker is lavishing a top exec with an eye-popping pay package. Despite the EpiPen scandal and a slumping stock price, Mylan (MYL) rewarded …
During the public outcry that followed, CEO Heather Bresch was called to testify before Congress in fall 2016 and Mylan's stock price was hammered. Still, the price of an EpiPen didn't change, and Chairman and former CEO Robert Coury …
The generic drug company's move is a blow to the Tel Aviv Stock Exchange's recovery prospects. Generic drugs company Mylan has announced its intention of delisting from the Tel Aviv Stock Exchange. Mylan has been traded in Tel Aviv …
It noted that the company's market capitalization has swelled to more than $20 million from about $3 million over the last 15 years, and its stock price also has soared over the longer time frame. "During Mr. Coury's long tenure, Mylan has …
Mylan (MYL) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Mylan (MYL) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
(MENAFN Editorial) HERTFORDSHIRE, England and PITTSBURGH, Nov. 10, 2017 /PRNewswire/ --Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is voluntarily delisting the company's ordinary shares from trading on the Tel Aviv …
MENAFN6mon